Wolfgang Hofgaertner,
Managing Partner
MD

My experience

Prior to joining Med2Mark, led Cellular Therapeutics division of Celgene (CELG) as Chief Scientific Officer/VP R&D responsible for business and scientific strategy development with oversight of all clinical and preclinical research and development. Extensive US-based experience with immuno-oncology cell therapies (NK cells, T cells, gene editing) and other cellular approaches. Specific areas of expertise include discovery research, IND enabling studies, CMC, IND submissions, early-stage clinical development, translational studies, R&D portfolio management, organizational effectiveness, and R&D program leadership. 

Gained medical device experience as Medical Director Europe for Becton Dickinson (BDX). Developed cancer diagnostic at US start-up Aureon. Submitted 510(k) to FDA for extracellular matrix (ECM) based wound management device and established in-house GMP manufacturing capabilities. 

Completed MD and DSc at University of Freiburg, Germany. Board certified in Clinical Pathology in United States and Europe with residency training in clinical pathology and fellowship training in Microbiology at University of Washington. Fellowship training in Molecular Pathology at University of Pittsburgh.  

My areas of expertise

 Biopharmaceutical, device and immuno-oncology .

HEALTH ECONOMICS & HEALTH IMPACT ASSESSMENT

Strategic and executive leadership of cell therapy/biologics and medical device research and development groups within US regulatory environment.

GO-TO-MARKET STRATEGY


Scientific and medical expertise, especially in cell therapies, cellular immuno-oncology, immunotherapy, clinical pathology, genetic engineering, biomaterials, wounds management and tissue engineering. 

COMMERCIALISATION STRATEGY


Scientific, technical and commercial assessment of R&D portfolios.

FINANCIAL SUPPORT & ADOPTION


In- & out-licensing opportunity assessments.